Sumit Chanda earned his Ph.D. from Stanford University in 2001, and received his post-doctoral training at the Genomics Institute of the Novartis Research Foundation (GNF). He subsequently transitioned to a Group Leader position, and established his research group in the Division of Cellular Genomics at GNF. In 2007, he joined the Infectious and Inflammatory Disease Center at Sanford-Burnham Medical Research Institute as an Associate Professor. Dr. Chanda also holds an Adjunct Professor appointment at the Salk Institute for Biological Studies, as well as a Visiting Scientist position at the Genomics Institute of the Novartis Research Foundation.
Title |
Cited By |
Year |
---|
A Nature study shows that the leprosy drug clofazimine, which is FDA approved and on the World Health Organization’s List of Essential Medicines, exhibits potent antiviral activities against SARS-CoV-2 and prevents the exaggerated inflammatory response associated with severe COVID-19. Based on these findings, a Phase 2 study evaluating clofazimine as an at-home treatment for COVID-19 could begin immediately.
16-Mar-2021 06:00:46 AM EDT
“These are antivirals that were developed for other viruses and now they’re being repurposed. Typically, a drug discovery effort takes five to 10 years, I think our best shot right now to get something to market and into patients quickly is to take old drugs and see if they work against the current Coronavirus that’s circulating.”
- Media Invited to Ask Questions - COVID-19 Testing, Drug Discovery, Infectiousness, and more
“If they can knock down the virus, we know that there is a safety record associated with these compounds and these can be very quickly developed into clinical candidates that can go into clinical trials for testing to see if they work in humans.”
- Media Invited to Ask Questions - COVID-19 Testing, Drug Discovery, Infectiousness, and more